We serve Chemical Name:cesium oxalate CAS:1068-63-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:cesium oxalate
CAS.NO:1068-63-9
Synonyms:Caesiumdichloriodid;EINECS 213-950-8;Cesium dichloroiodide;dicesium oxalate;MFCD00054352;Cesiumoxalate;caesium oxalate;caesium(1+) dichloroiodanuide;Caesiumoxalat;Cesium dichloroiodate;caesium iodide dichloride
Molecular Formula:C2CsO4–
Molecular Weight:220.92400
HS Code:2917119000
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:80.26000
Exact Mass:220.88500
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2923 8/PG 3
Packing Group:III
Contact us for information like Caesiumdichloriodid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,caesium iodide dichloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,caesium iodide dichloride Use and application,caesium(1+) dichloroiodanuide technical grade,usp/ep/jp grade.
Related News: Once they have decided how to make the compound, our staff in the production department manufacture a high quantity of APIs using the large reactors in our plant. cesium oxalate manufacturer INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. cesium oxalate supplier Once they have decided how to make the compound, our staff in the production department manufacture a high quantity of APIs using the large reactors in our plant. cesium oxalate vendor INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. cesium oxalate factory The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed.
